Astrazeneca (AZN) Capital Expenditures Growth (5y) (2014 - 2026)
Astrazeneca (AZN) Capital Expenditures Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.77% |
| Dec 31, 2025 | 24.07% |
| Jun 30, 2025 | 68.12% |
| Mar 31, 2025 | -25.33% |
| Dec 31, 2024 | 71.77% |
| Sep 30, 2024 | 12.88% |
| Mar 31, 2024 | -19.10% |
| Dec 31, 2021 | 46.04% |
| Mar 31, 2021 | 2.23% |
| Dec 31, 2020 | -1.13% |
| Jun 30, 2020 | 9.57% |
| Mar 31, 2020 | 5.45% |
| Dec 31, 2019 | -16.74% |
| Sep 30, 2019 | -30.04% |
| Mar 31, 2019 | 1.00% |
| Sep 30, 2018 | -48.64% |
| Dec 31, 2016 | -10.23% |
| Mar 31, 2016 | -3.86% |
| Dec 31, 2015 | 48.36% |
| Sep 30, 2015 | -12.53% |